Superantigens exert their pathologic effects by direct binding to major histocompatibility complex (MHC) class II molecules and T cell antigen receptors (TCR), thus circumventing the normal, antigen-specific immune response. A direct link between disease and toxin suggests an excellent opportunity for vaccine intervention. Site-directed mutants of staphylococcal enterotoxin A (SEA) that have attenuated binding to either the TCR or the MHC class II molecule were developed. Both kinds of SEA mutants induced high levels of antibody against SEA when used as vaccines, and the immunized animals were fully protected when challenged with wild type toxin. However, a residual lethality was associated with the attenuated TCR-binding mutant. These results, combined with an understanding of the molecular nature of superantigen and receptor interactions, indicate that targeting MHC class II binding by site-directed mutagenesis will produce the most effective vaccine.
Superantigens exert their pathologic effects by direct binding to major histocompatibility complex (MHC) class II molecules and T cell antigen receptors (TCR), thus circumventing the normal, antigen-specific immune response. A direct link between disease and toxin suggests an excellent opportunity for vaccine intervention. Site-directed mutants of staphylococcal enterotoxin A (SEA) that have attenuated binding to either the TCR or the MHC class II molecule were developed. Both kinds of SEA mutants induced high levels of antibody against SEA when used as vaccines, and the immunized animals were fully protected when challenged with wild type toxin. However, a residual lethality was associated with the attenuated TCR-binding mutant. These results, combined with an understanding of the molecular nature of superantigen and receptor interactions, indicate that targeting MHC class II binding by site-directed mutagenesis will produce the most effective vaccine.
Bacterial superantigens are ligands for both major histocompatibility complex (MHC) class II molecules, expressed on antigen-presenting cells, and the variable portion of the T cell antigen receptor (3 chain (TCR V(3) [1 -4] . Each bacterial superantigen has a distinct affinity to a set of TCR V j3, and coligation ofthe MHC class II molecule polyclonally stimulates T cells [5] [6] [7] . Pathologically elevated levels of cytokines that are produced by activated T cells are the probable cause of toxic shock symptoms [8, 9] . In addition, susceptibility to lethal gram-negative endotoxin shock is enhanced by several bacterial superantigens [9] .
Staphylococcal enterotoxins (SEs) A through E are the most common cause of food poisoning [10] and are associated with several seri ous diseases [11, 12] , such as bacterial arthritis [13, 14] , other autoimmune disorders [15] , and toxic shock syndrome [16, 17] . The nonenterotoxic staphylococcal superantigen toxic shock syndrome toxin-l was first identified as a causative agent of menstrual-associated toxic shock syndrome [18] . Superantigen-producing Staphylococcus aureus strains are also linked to Kawasaki syndrome, an inflammatory disease of children [19] . Although antibodies reactive with superantigen are present at low levels in human sera [20] , boosting antibody titers by specific immunization may be efficacious for patients at risk for toxic shock syndrome and the other disorders of common etiology.
A vaccine approach to controlling bacterial superantigenassociated diseases presents a unique set of challenges. Acute exposure to bacterial superantigens produces T cell anergy [21] , yet T cell help is presumably a requirement for mounting an antibody response. The superantigen vaccines used in this study were developed by engineering changes in the receptor-binding portions of SEA to reduce receptor-binding affinities and toxicity while maintaining antigenicity.
A three-dimensional structural homology model of SEA complexed with the MHC class II molecule was developed [22] from the structural alignment of SEA and unbound SEB molecules [23] and cocrystallographic data of the complex between SEB and the human MHC class II molecule, HLA-DRI [24] . MHC class II molecule and TCR-binding modes, confirmed by site-specific mutagenesis, are conserved between SEB and SEA [22] . The MHC class Il-sbinding surface of SEA and SEB consists of a conserved polar pocket and hydrophobic loop. Mutation of a critical tyrosine (SEA residue 92) within the polar pocket is postulated to disrupt hydrogen bonding to lysine 39 of the DRa subunit and results in a 1000-fold reduction in SEA binding affinity. TCR interactions map to nonconserved residues within a shallow surface cavity of SEA [12] and SEB [25] . Thus, the mutation tyrosine 64 to alanine, within this site of SEA, results in diminished T cell recognition [12] .
Immunization strategies based on attenuation of either TCR or MHC class II receptor binding were compared. We determined whether antibody responses to both types of engineered vaccines protected immunized mice from SEA challenge.
Materials and Methods
SEA mutants. The production of SEA wild type (WT) or mutant genes and protein expression in Escherichia coli were done as described [22] . In brief, bacteria were grown to an A 600 of 0.5-0.6 in Terrific Broth (Difco, Detroit) containing 50 j..lg/mL ampicillin. Bacteria were collected by centrifugation, washed with 30 mMNaCI and 10 mM TRIS (pH 7.6), and pelleted by centrifugation. Periplasmic proteins were recovered from the bacterial pellet as described [22] and concentrated (Centriprepl0; Amicon, Beverly, MA).
The SEA preparations were partially purified by CM Sepharose (Sigma, St. Louis) chromatography, using a linear gradient of 10-50 mM potassium phosphate (pH 5.8-7.4). The partially purified SEA was further purified by preparative isoelectric focusing (MinipHor; Rainin Instrument, Woburn, MA). The MinipHor was loaded with the SEA-enriched fraction from CM Sepharose chromatography in a solution containing 10% (vol/vol) glycerol and 1% (vol/vol) ampholytes, pH 6-8 (Protein Technologies, Tucson). The protein preparations were allowed to focus until equilibrium was reached (~4 h, 4°C). Twenty focused fractions were collected, and aliquots of each were analyzed by SDS-PAGE and immunoblotting (as described below). The SEA-containing fractions were pooled and refocused for an additional 4 h. The fractions containing purified SEA were pooled and dialyzed first against 1 MNaCI (48 h, 4°C) to remove ampholytes and then against buffer consisting of 50 mM sodium phosphate and 140 mM sodium chloride, pH 7.4 (PBS), for 12 h at 4°C.
The concentrations of recombinant proteins were determined by the bicinchoninic acid method (Pierce, Rockford, IL) and quantitative immunoblotting, using an affinity-purified anti-SEA antibody and the WT SEA as a standard protein, as described below. All protein preparations were >99% pure, as judged by SDS-PAGE and Western immunoblotting.
Gel electrophoresis and immunoblotting analysis. The SEA preparations were analyzed by SDS-PAGE (12%) and stained with Coomassie brilliant blue R-250 (Sigma) in methanol (10% vol/ vol) acidic acid (10% vol/vol). The proteins separated by SDS-PAGE (not stained) were transferred to nitrocellulose membranes (Bio-Rad, Melville, NY) by electroblotting, and the membranes were then blocked (12 h, 4°C) with 0.2% casein in PBS. The membrane was then incubated (1 h, 37°C, shaking) with 2 jLg/mL affinity-purified anti-SEA antibody (Toxin Technology, Sarasota, FL) in PBS with 0.02% casein. After the membranes were thoroughly washed, peroxidase-conjugated goat anti-rabbit IgG (Cappel/Organon Teknika, West Chester, PA) was added (1:5000) and the membranes were incubated for 1 h (37°C) with shaking. The unbound antibody was removed by washing with PBS, and bound antibody was visualized by using a Bio-Rad peroxidase development kit. For quantitation, dilutions of SEA preparations were immobilized on nitrocellulose membranes by using a slot-blot apparatus (Bio-Rad). The membrane was removed from the slot-blot apparatus, and unreacted sites were blocked (12 h, 4°C) with 0.2% casein in PBS. After washing once with the PBS, the membrane was incubated (1 h, 37°C) with 2 jLg/mL rabbit affinity-purified anti-SEA antibody (Toxin Technology) in PBS that contained 0.02% casein. After four washes, the bound rabbit antibody was reacted with goat anti-rabbit IgG conjugated with horseradish peroxidase (1 h, 37°C), and the blots were developed using enhanced chemiluminescence (Amersham Life Sciences, Arlington Heights, IL). The amount of WT SEA or mutant protein was measured by densitometry (NIH Image 1.47 software) of exposed radiographic film. Standard curves were prepared by plotting the mean of duplicate densitometric readings for each dilution of WT SEA standard.
The resulting values were fitted to a straight line by linear regression. Concentrations of SEA mutant proteins were determined by comparing mean values of various dilutions of the mutant to the standard curve.
Biologic activities and immunizations. Male C57BL/6 mice, 10-12 weeks old, were obtained from Harlan Sprague-Dawley (Frederick Cancer Research and Development Center, Frederick, MD). The lethal effect of WT or mutant SEA was evaluated as described for WT SEA [9] . For immunizations, mice were given by intraperitoneal injection either 2 or 10 jLg of WT or mutant SEA protein in 100 JLL of RIBI adjuvant (RIB I Immunochem Research, Hamilton, MT), or adjuvant only, and boosted intraperitoneally at 2 and 4 weeks. Serum was collected from tail veins 1 week after the last immunization. Mice were challenged 2 weeks after the last injection with WT SEA (10 jLg) and lipopolysaccharide (LPS, 150 jLg) from E. coli 055:B5 (Difco) as described [9] . Challenge controls were adjuvant-immunized or nonimmunized mice injected with both agents (100% lethality) or with either SEA or LPS. No lethality was produced by these negative controls.
Antibody assay. Microtiter plates were coated with 1 jLglwell WT SEA in 100 JLL of PBS (37°C, 2 h). After antigen coating, the wells were blocked with 250 JLL of casein 0.2% in PBS for 4 h at 37°C and then washed four times with PBS containing 0.2% Tween 20. Immune or nonimmune mouse sera were diluted in PBS containing 0.02% casein, and 100 JLL of each dilution was added to duplicate wells. After each well was washed four times, bound antibody was detected with horseradish peroxidase (Sigma)-labeled goat anti-mouse IgG (37°C, 1 h), using o-phenylenediamine as the chromogen. The mean of duplicate optical densities (absorbance at 490 nm) of each treatment group was determined, and these data were compared on the basis of the inverse of the highest serum dilution that produced an optical density reading four times above the negative control wells. For negative controls, antigen or serum was omitted from the wells.
T lymphocyte proliferation assay. Splenic mononuclear cells were obtained as described [9] . Briefly, mononuclear cells were isolated by buoyant density centrifugation (Sigma) and washed three times. The cells were resuspended in medium containing 5% fetal bovine serum, and 100 JLL (4 X 10 5 cells) of the cell suspension was added to triplicate wells of 96-well flat-bottom plates. The mononuclear cells were cultured (37°C, 5% CO 2 ) with WT or mutant SEA. After 3 days the cultures were pulsed (12 h) with 1 jLCi/well eH]thymidine (Amersham), and incorporated radioactivity was measured by liquid scintillation.
SEA binding and TeR subset analysis. Cells from the mouse B lymphoma line A20 (2-4 X 10 5 cells) were incubated (40 min at 37°C) with WT or mutant SEA in Hanks' balanced salt solution containing 0.5% bovine serum albumin (HBSS). The cells were washed with HBSS and incubated with 5 jLg of affinity-purified anti-SEA antibody in HBSS (4°C, 45 min). Unbound antibody was removed, and the bound antibody was detected with fluorescein isothiocyanate-labeled goat anti-rabbit IgG (Organon Teknika). Unbound antibody was removed and the cells were analyzed by a FACSort flow cytometer (Becton Dickinson, Mountain View, CA).
For TCR subset analysis, splenic mononuclear cells were obtained from mice immunized with WT or mutant SEA. The mononuclear cells were incubated (37°C) with WT SEA (100 ng/mL) for 5 days and then cultured in 85% RPM I 1640 and 10% interleukin-2 supplement (Advanced Biotechnologies, Columbia, MD) with 5% fetal bovine serum for an additional 5 days. The T cells were Figure 1 . Positions of amino acid residues that have been mutated in staphylococcal enterotoxin A (SEA) vaccines. Residue K l4E is located in N-terminal peptide of SEA that does not interact with either major histocompatibility complex (MHC) class IT molecule or T cell receptor (TCR) . Residue Y64A is involved in TCR interactions. while residue Y92A is critical for MHC class II binding [22] .
washed twice and stained with anti-TCR (Biosource, Camarillo, CA) or anti-V,B-specific TCR (45 min, 4°C). All cells analyzed were positive for the T cell marker C03 and expressed the CD25 activation marker (data not shown). Controls were incubated with an isotype-matched antibody of irrelevant specificity. Unreacted antibody was removed, and the cells were incubated with a fluorescein isothiocyanate-Iabeled anti-mouse IgG (Organon Teknika) on ice for 30 min. The cells were washed and analyzed by flow cytometry (FACSorl).
Results
Sh.'A mutants. The predicted structure of SEA in complex with the human MHC class II molecule HLA-DRI is shown in figure I . For clarity, only the ORa features most critical to SEA binding and the location of the mutated SEA amino acids are shown. Substituting SEA tyrosine 92 with alanine (Y92A) reduces DRI binding lOOO-fold [22] . Tyrosine 64 is located in a site that interacts with TCRs, and mutation to alanine (Y64A) substantially reduced human T cell responses [22] . Lysine 14 is located at the N-terminus of SEA in a region exhibiting weak secondary structure and does not participate in interactions with the MHC class II molecule or TCR [22] . Wo.: therefore mutated lysine 14 to glutamic acid (K 14E) and used this SEA mutant as a control.
After purification, a single homogenous protein band, migrating just under 30 kDa, was detected for WT or mutant SEA by SDS-PAGE ( figure 2A) . A faint second 60-kDa band, corresponding to the previously reported molecular dirner of SEA [26] , was observed with Western blots probed with anti-SEA antibody (figure 28).
TCR and MHC class II binding ofengineered SEA mutants. The binding of WT or mutant SEA was evaluated with the MHC class II -expressing murine 8 cell lymphoma cell line A20 ( figure 3) . The binding affinity of WT SEA to mouse MHC class II (H-2.!) molecules was lower than that observed with human MHC class II -expressing cells (data not shown), reflecting the reduced toxicity that bacterial supcrantigcns exert in mice [9] . WT SEA , Y64A, and K 14E all had the same relative affinity to mouse MHC class II molecules. Similar to the results obtained with human MIIC class II molecules [22] , the Y92A, when compared with WT SEA, mutant exhibited substantially reduced binding to A20 cells ( figure 3 ).
The effect of WT SEA or site-specific SEA mutants on splenic mononuclear cells obtained from nonimrnunized C57BLl6 (I-l_2 b ) mice is shown in figure 4 . Both WT SEA and the control mutant K 14E were potent T cell activators. effective at minimal concentrations of 10-100 pg/mL. However, T cell responses to Y92A were reduced at least IOO-fold compared with responses to WT SEA, while Y64A-stimulated responses were slightly higher than those to Y92A. These results confirmed that attenuation of superantigen binding to either MHC class 11 or TCR molecules resulted in dramatically reduced mouse T cell proliferation. To investigate the physiologic effects of the attenuated SEA mutants, toxicities were examined in vivo (table I) of LPS from gram-negative bacteria, a fatal toxic shock results that is characterized by elevated levels of pro inflammatory cytokines such as tumor necrosis factor-a, interleukin-6, and interferon-y [9] . The SEA concentration that was selected for this experiment represents 10 t.n., [9] . • Reciprocal of serum dilution resulting in optical density reading fourtimes above negative controls (wells containing either no SEA or no primary antibody).
--------------------------------------,
munized with WT or mutant SEA. Control mice received adjuvant only or were left untreated. One week before challenge with WT SEA, blood samples were taken from mice , and serum antibody titers were determined for each group (table 2) . Mice immunized with 2 j.tg of Y64A or Y92A had serum antibody titers of I :5000 and 1:1000, respectively . Immunization with 2 j.tg of WT SEA or control mutant resulted in titers of 1:5000 and I: 10,000, respectively. The highest immunizing dose (10 j.tg/mouse) was most effective for all animals, resulting in antibody titers > I : I0,000. All mice were challenged with 10 LD so of WT SEA (potentiated with LPS). The survival dat a correlated well with the levels of serum antibodies in immunized mice. All mice that were vaccinated with 10 j),g of Y64A or Y92A survived the lethal challenge dose of WT SEA. Slightly less protection was affo rded by the lower vaccination dose of mutant Y64A or Y92A. All mice immunized with both doses of WT SEA survived the lethal challenge with WT SEA. Mice immunized with mutant K14E exhibited survivals of 100% and 80% for high and low vaccination dos es, respectively. All nonimmunized or control mice that were vaccinated with adjuvant alone died when challenged with WT SEA and a potentiating dose of LPS.
Immune recognition ofsuperantigen mutants. Bacterial superantigens induce clonal anergy of specific subsets of T cells in mice. It was po ssible that the loss of sensitivity to WT SEA among the mice vaccinated with the attenuated mutant forms represented a state of specific nonresponsiveness instead of sp ecific immunity. To address this issue, lymphocyte responses to WT SEA were m easured with splenic mononuclear cells collected 2 weeks afte r the third immunizati on (figure 5). As expected, lymphocytes from mice that were immunized with WT SEA or control SEA mutant showed little to no proliferation when incubated with the WT superantigen . In contrast, lymphocytes obtained from control mice or tho se im mu nized with eith er Y64A or Y92 A all responded vigoro usly to the WT SEA ( figure 5) . Th e TCRs used by T cells from the SEAvaccinated mice were then characterized by flow cytometry. T cells from immunized or control mice were incubated with WT SEA in culture for 7 days , followed by a 5-day expansion in interleukin-2-contain ing medium. Distinct populations of activated TCR V(31I -positive cell s were observed with T cell s from mice immunized with Y92 A and Y64A (figure 6), representing 4S% and 40'% of T cells, res pe ctively. However, V(3II-expressing ce lls obtained from WT SE A -or Kl4E-immunized mice were~1% and 6% of the total T cell population, respectively, sugges ting that this subset was nonresponsive to restimulation with the WT superantigen . T cells bearing V(317a, 3, 7, and lOb were unchanged for all mice (data not shown). It was apparent that T ce ll responses to both the TCR and MH C cla ss II bind ing -attenuated SEA mutants were similar to each other but differed from responses to control or WT molecules. Th ese results sugg ested convent ional anti gen-proce ssing was ... functioning in presentation of the superantigen mutants Y64A and Y92A.
Discussion
Binding of SEA and other superantigens to HLA-DR molecules is characterized by a fast on-rate and high affinity [27] . All defined bacterial superantigens interact with MHC class II molecules by means of a common DRa subunit binding mode, with additional stabilizing interactions that are unique to each [12] . A second, zinc-dependent, DR,g subunit binding mode for SEA, SED, and SEE [28] increases MHC class II binding but is not directly involved with T cell signaling. Both the Y92A and Y64A mutants used in the present study were expected to bind to the DR,g subunit because the residues required to form the zinc coordination complex have not been altered. The leucine at position 48 of SEA is located in a solventexposed reverse-turn on the surface of the molecule (the hydrophobic binding loop), and this structural motif is conserved among all bacterial superantigens [12] . The hydrophobic binding loop and the residues forming the polar binding pocket are likely to be the most important structural features driving strong interactions with the DRa subunit [22] .
Antigen presentation molecules of the MHC play a critical role in controlling immune responses by selectively activating T cells that express receptors complimentary to bound peptides. In contrast, superantigens activate T cells with little apparent regard for antigen specificity. For SEA, the dominant TCR subsets that are activated include V,gl, 3, 10, 11, 12, and 17 [7] . Direct ligation of T cell antigen receptors, independent of MHC molecules, may occur in some cases [29] . However, by targeting MHC class II molecules, a more effective subterfuge of the immune response occurs. Peptides presented by MHC class II molecules in some cases are sterically blocked by bound bacterial superantigens [30, 31] , thus circumventing the normal immune recognition of antigens. The responding lymphocytes are subsequently removed from their role as effector cells. Most T cells that are activated by superantigen are eliminated by a Fas/Fas ligand-dependent apoptosis [32] , or they may enter into a state of specific nonresponsiveness. However, as our data demonstrated, when the strong MHC class II receptor interactions were attenuated by site-directed mutagenesis, the superantigen was effectively recognized by the immune system and an appropriate antibody response ensued. Although T cell anergy was not apparent when the SEA mutant Y64A was used as an immunogen, a residual amount of toxicity was observed compared with the results obtained with the MHC class IIbinding mutant Y92A. Because TCR-binding modes of superantigens are not conserved [22] , mutating key amino acid residues in these sites may actually result in the acquisition of a new TCR recognition repertoire [25] . Therefore, our results indicate that attenuation of MHC class II binding provides the best route for vaccine development.
The first critical step in SEA activation of T cells is binding of the superantigen to the MHC class II molecule. Antibody inhibition of this interaction should be sufficient to prevent initiation of the disease sequelae. Based on structural homologies, it is conceivable that antibody responses against one superantigen will protect against other bacterial superantigens. If this proves to be correct, then a multivalent vaccine made up of a minimal combination of superantigen subunits, with attenuated MHC class II binding, may be effective against the majority of superantigens. However, the protein surfaces that are predicted to interact with TCRs are not conserved [22] , suggesting that a vaccine strategy targeting T cell interactions is likely to be effective only for a limited number of superantigens.
Mice immunized with the attenuated SEA mutant Y92A were fully protected from challenge with the WT toxin, and high levels of antibody against WT SEA were detected in the sera of all mice receiving the vaccine. Therefore, we conclude that immunization with the nonsuperantigenic form of SEA can elicit a strong neutralizing antibody response. In addition, Y64A and Y92A did not induce T cell anergy. T cell responses of both WT and control SEA-vaccinated mice were depleted of V(311 T cells, while this population of lymphocytes was highly responsive in mice immunized with the mutants Y64A or Y92A. This observation indicates that anergy induction in vivo requires engagement of both TCR and MHC class 11 molecule. These data also suggested that these two mutants were potent immunogens because conventional processing and presenting to T cells had occurred.
It is known that primates are most sensitive to SEA and related bacterial superantigens; therefore, it will be necessary to also address toxicity and immunogenicity issues directly in these species. Finally, we anticipate that the availability of a potential superantigen vaccine will allow a direct assessment of the putative role of these bacterial products in a number of human diseases.
